Article Text

Download PDFPDF
Contributing factors to personalised medicine in atrial fibrillation
  1. Jeroen M Hendriks1,2,
  2. Adrian D Elliott2,
  3. Melissa E Middeldorp2,3,
  4. Prashanthan Sanders2
  1. 1Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia
  2. 2Centre for Heart Rhythm Disorders, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia
  3. 3Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
  1. Correspondence to Professor Jeroen M Hendriks, Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia; jeroen.hendriks{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

It has now been established that atrial fibrillation (AF) is a chronic condition, associated with significant cardiovascular comorbidities and lifestyle factors. This underlying substrate contributes to the fact that it is considered a progressive condition. International guidelines have recommended a holistic and comprehensive treatment approach that goes beyond the treatment of symptoms and thus the arrhythmia alone but also includes prevention of thromboembolic complications and identification and management of risk and lifestyle factors, contributing to the progression of AF.1

Nguyen and colleagues2 outline the development of a prediction model for AF progression and further explore the associated contribution of underlying pathophysiological mechanisms. They performed an interim analysis of the Reappraisal of AF: Interaction between Hypercoagulability, Electrical Remodelling, and Vascular Destabilisation in the Progression of AF (RACE V Study), which aims to investigate the association of clinical factors and biomarkers related to the progression of AF in patients diagnosed with self-terminating (paroxysmal) AF. These patients underwent extensive clinical assessment and phenotyping at baseline and ongoing rhythm monitoring by means of a Medtronic Reveal LINQ implantable loop recorder or Medtronic pacemaker during at least 1-year follow-up. The phenotyping included diagnostic tests such as ECG, echocardiography, vascular assessment and a CT scan, as well as extensive blood biomarker assessment. Progression of AF was defined as development of persistent or permanent AF during follow-up, or an increase in AF burden of >3% over the first 6 months or total follow-up. In total, 417 patients were included in the analysis, median age 65 (58–71) years and 43% were …

View Full Text


  • Twitter @, @Elliott_AD, @melissaemm1, @PrashSanders

  • Contributors All authors contribute to this manuscript and have approved this final version for submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Arrhythmias and sudden death
    Bao-Oanh Nguyen Vanessa Weberndorfer Harry JGM Crijns Bastiaan Geelhoed Hugo Ten Cate Henri Spronk Abraham Kroon Ruben De With Meelad Al-Jazairi Alexander H Maass Yuri Blaauw Robert G Tieleman Martin E W Hemels Justin Luermans Joris de Groot Cornelis P Allaart Arif Elvan Mirko De Melis Coert Scheerder Anton Jan van Zonneveld Ulrich Schotten Dominik Linz Isabelle Van Gelder Michiel Rienstra